Flagship Harbor Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.33M | Buy |
8,408
+201
| +2% | +$27.2K | 0.05% | 291 |
|
|
2026
Q1 | $1.05M | Buy |
8,207
+1,890
| +30% | +$236K | 0.05% | 302 |
|
|
2025
Q4 | $770K | Sell |
6,317
-5,756
| -48% | -$660K | 0.04% | 351 |
|
|
2025
Q3 | $1.21M | Sell |
12,073
-5,342
| -31% | -$481K | 0.05% | 275 |
|
|
2025
Q2 | $1.44M | Sell |
17,415
-241
| -1% | -$19.2K | 0.07% | 247 |
|
|
2025
Q1 | $1.43M | Sell |
17,656
-536
| -3% | -$47.9K | 0.08% | 231 |
|
|
2024
Q4 | $1.64M | Buy |
18,192
+8,938
| +97% | +$866K | 0.09% | 203 |
|
|
2024
Q3 | $914K | Sell |
9,254
-196,863
| -96% | -$19.3M | 0.05% | 277 |
|
|
2024
Q2 | $19.1M | Buy |
206,117
+199,262
| +2,907% | +$17.9M | 1.15% | 18 |
|
|
2024
Q1 | $650K | Buy |
6,855
+641
| +10% | +$59.5K | 0.04% | 323 |
|
|
2023
Q4 | $555K | Buy |
6,214
+273
| +5% | +$20.3K | 0.04% | 340 |
|
|
2023
Q3 | $434K | Buy |
5,941
+577
| +11% | +$46.1K | 0.04% | 369 |
|
|
2023
Q2 | $446K | Sell |
5,364
-1,083
| -17% | -$90.6K | 0.04% | 370 |
|
|
2023
Q1 | $491K | Sell |
6,447
-206
| -3% | -$17.1K | 0.05% | 355 |
|
|
2022
Q4 | $552K | Sell |
6,653
-172
| -3% | -$13.9K | 0.06% | 311 |
|
|
2022
Q3 | $541K | Sell |
6,825
-671
| -9% | -$56.6K | 0.06% | 292 |
|
|
2022
Q2 | $557K | Buy |
7,496
+1,348
| +22% | +$101K | 0.06% | 309 |
|
|
2022
Q1 | $553K | Buy |
6,148
+741
| +14% | +$68.4K | 0.05% | 328 |
|
|
2021
Q4 | $605K | Sell |
5,407
-479
| -8% | -$57.8K | 0.06% | 319 |
|
|
2021
Q3 | $797K | Hold |
5,886
| – | – | 0.09% | 254 |
|
|
2021
Q2 | $797K | Buy |
5,886
+64
| +1% | +$8.41K | 0.09% | 255 |
|
|
2021
Q1 | $790K | Buy |
5,822
+1,159
| +25% | +$174K | 0.09% | 246 |
|
|
2020
Q4 | $656K | Sell |
4,663
-10,867
| -70% | -$1.39M | 0.08% | 255 |
|
|
2020
Q3 | $1.73M | Buy |
15,530
+2,505
| +19% | +$281K | 0.23% | 86 |
|
|
2020
Q2 | $1.46M | Buy |
13,025
+7,030
| +117% | +$692K | 0.21% | 100 |
|
|
2020
Q1 | $464K | Buy |
5,995
+2,633
| +78% | +$233K | 0.09% | 210 |
|
|
2019
Q4 | $320K | Sell |
3,362
-325
| -9% | -$28.1K | 0.06% | 325 |
|
|
2019
Q3 | $281K | Sell |
3,687
-420
| -10% | -$34.9K | 0.06% | 333 |
|
|
2019
Q2 | $360K | Sell |
4,107
-2,189
| -35% | -$187K | 0.07% | 270 |
|
|
2019
Q1 | $570K | Buy |
6,296
+329
| +6% | +$28K | 0.12% | 190 |
|
|
2018
Q4 | $428K | Sell |
5,967
-56
| -0.9% | -$4.51K | 0.1% | 214 |
|
|
2018
Q3 | $570K | Buy |
6,023
+270
| +5% | +$26.2K | 0.11% | 208 |
|
|
2018
Q2 | $547K | Sell |
5,753
-130
| -2% | -$11.9K | 0.11% | 198 |
|
|
2018
Q1 | $494K | Buy |
5,883
+235
| +4% | +$21.5K | 0.15% | 174 |
|
|
2017
Q4 | $484K | Sell |
5,648
-200
| -3% | -$16.8K | 0.14% | 176 |
|
|
2017
Q3 | $516K | Sell |
5,848
-145
| -2% | -$11.6K | 0.17% | 155 |
|
|
2017
Q2 | $462K | Sell |
5,993
-10
| -0.2% | -$709 | 0.16% | 161 |
|
|
2017
Q1 | $403K | Sell |
6,003
-65
| -1% | -$4.37K | 0.15% | 168 |
|
|
2016
Q4 | $384K | Buy |
+6,068
| New | +$375K | 0.17% | 163 |
|
Other funds holding XBI
JFG
Flagship Harbor Advisors's XBI Position: Q2 2026 in Review
Flagship Harbor Advisors increased its State Street SPDR S&P Biotech ETF (XBI) stake by 2.4% in Q2 2026, buying an estimated $27.2K and bringing the position to 8,408 shares worth $1.33M. The position accounts for 0.05% of the portfolio, ranked #291.
Flagship Harbor Advisors first reported a position in XBI in Q4 2016 and has held it in 39 quarters since. The position peaked at $19.1M in Q2 2024. 932 funds tracked by Wall St. Rank hold XBI as of Q2 2026.
- Flagship Harbor Advisors held 8,408 shares of State Street SPDR S&P Biotech ETF worth $1.33M as of Q2 2026.
- Flagship Harbor Advisors bought 201 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $27.2K.
- State Street SPDR S&P Biotech ETF made up 0.05% of Flagship Harbor Advisors's portfolio in Q2 2026, its #291 holding.
- Flagship Harbor Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q4 2016 and has held it in 39 quarters since.
- Flagship Harbor Advisors's State Street SPDR S&P Biotech ETF position peaked at $19.1M in Q2 2024.
- 932 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.
Based on Flagship Harbor Advisors's 13F filing for Q2 2026, filed 22 Jul 2026.